THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

There's no shortage of cancer immunotherapies ... Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Helping Libtayo reach its potential was a 2022 nod to treat newly diagnosed non-small cell lung cancer (NSCLC), allowing it to compete with Merck’s powerhouse PD-1 drug Keytruda. More growth ...

Adjuvant treatment with cemiplimab (Libtayo) significantly improves disease-free survival (DFS ... of medical oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia.

Libtayo is designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation and already holds approvals to treat certain patients with advanced CSCC. C-POST met its primary ...

Department of Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia, and lead investigator of the trial. “At the first prespecified interim analysis, Libtayo achieved a ...

It also is approved for treatment of certain patients with basal cell carcinoma or non-small cell lung cancer ... Libtayo achieved a remarkably high bar in improving disease-free survival in ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...